GlassScriptPhysician profile
Yassar Almanaseer
NPI 1467585349
$7,179.39
in general payments reported to CMS, 2019-2025
10 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,342 · 2020: $492 · 2021: $462 · 2022: $608 · 2023: $901 · 2024: $1,199 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,827.99 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Medtronic, INC. | $1,734.52 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $1,509.74 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Versacross Access Solution |
| Shockwave Medical, INC | $829.44 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $551.25 | 2019-2020 | |
| Abbott Laboratories | $345.07 | 2019-2025 | Cardiomems |
| Cvrx, INC. | $187.73 | 2023-2024 | Barostim Neo System |
| Abiomed | $144.09 | 2022-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $32.63 | 2021-2025 | Eliquis |
| Cardiovascular Systems INC. | $16.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yassar Almanaseer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.